JP2007500132A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500132A5
JP2007500132A5 JP2006521282A JP2006521282A JP2007500132A5 JP 2007500132 A5 JP2007500132 A5 JP 2007500132A5 JP 2006521282 A JP2006521282 A JP 2006521282A JP 2006521282 A JP2006521282 A JP 2006521282A JP 2007500132 A5 JP2007500132 A5 JP 2007500132A5
Authority
JP
Japan
Prior art keywords
ldcam
crtam
polypeptide
dendritic cell
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500132A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/023822 external-priority patent/WO2005012530A2/en
Publication of JP2007500132A publication Critical patent/JP2007500132A/ja
Publication of JP2007500132A5 publication Critical patent/JP2007500132A5/ja
Pending legal-status Critical Current

Links

JP2006521282A 2003-07-25 2004-07-23 Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法 Pending JP2007500132A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49002703P 2003-07-25 2003-07-25
PCT/US2004/023822 WO2005012530A2 (en) 2003-07-25 2004-07-23 Antagonists and agonists of ldcam and methods of use

Publications (2)

Publication Number Publication Date
JP2007500132A JP2007500132A (ja) 2007-01-11
JP2007500132A5 true JP2007500132A5 (cg-RX-API-DMAC7.html) 2007-09-06

Family

ID=34115346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521282A Pending JP2007500132A (ja) 2003-07-25 2004-07-23 Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法

Country Status (9)

Country Link
US (2) US7267960B2 (cg-RX-API-DMAC7.html)
EP (2) EP2133362B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007500132A (cg-RX-API-DMAC7.html)
AT (1) ATE554108T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004261941B2 (cg-RX-API-DMAC7.html)
CA (1) CA2533512C (cg-RX-API-DMAC7.html)
ES (1) ES2383328T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000974A (cg-RX-API-DMAC7.html)
WO (1) WO2005012530A2 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345328A1 (en) 2001-06-27 2003-03-03 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
AU2006216291B2 (en) * 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
EP2069793B9 (en) 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
JP2010503490A (ja) * 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド 調整可能な表面特徴を備えた内部人工器官
ATE517590T1 (de) 2006-09-15 2011-08-15 Boston Scient Ltd Biologisch erodierbare endoprothesen
WO2008034031A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
JP2010503491A (ja) 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド 生物学的安定性無機層を有する生浸食性エンドプロスシーシス
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
ATE488259T1 (de) 2006-12-28 2010-12-15 Boston Scient Ltd Bioerodierbare endoprothesen und herstellungsverfahren dafür
AU2008292854A1 (en) * 2007-08-30 2009-03-05 Genentech, Inc. Methods and compositions for modulating T cells
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US10457719B2 (en) * 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
WO2010101901A2 (en) 2009-03-02 2010-09-10 Boston Scientific Scimed, Inc. Self-buffering medical implants
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. Cadm1に特異的な完全ヒト抗体
SG10201404280XA (en) * 2009-07-21 2014-10-30 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
AU2010276264B2 (en) * 2009-07-21 2013-09-19 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
WO2011119573A1 (en) 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR102493543B1 (ko) * 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
US20170022286A1 (en) * 2015-03-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of crtam agonists
CN107847711B (zh) * 2015-05-13 2021-06-15 英诺威讯有限公司 用于在导管、其它留置或植入装置及其它装置上抑制生物膜形成的系统
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
EP3704154A1 (en) 2017-11-02 2020-09-09 Oxford BioTherapeutics Ltd Antibodies and methods of use
CN108333132A (zh) * 2018-02-22 2018-07-27 哈尔滨工业大学 一种煤化工废水的生物毒性检测方法
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (en) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan BIOMATERIAL SENSOR SYSTEMS
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
CN116390754A (zh) * 2020-10-20 2023-07-04 莱兰斯坦福初级大学评议会 用于过继细胞治疗的可注射水凝胶
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023274286A1 (zh) * 2021-06-30 2023-01-05 南京圣和药业股份有限公司 抗crtam抗体及其应用
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Fcガンマ受容体II結合、及びグリカン含量
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1986000991A1 (en) 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP0716610B1 (en) 1993-08-26 2006-05-17 Genetics Institute, LLC Human bone morphogenetic proteins for use in neural regeneration
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5877155A (en) 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5686257A (en) * 1995-04-26 1997-11-11 Schering Corporation Binding compositions for mammalian T cell antigens and related reagents
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6642360B2 (en) * 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US20030040038A1 (en) 1997-08-22 2003-02-27 Steven F. Dowdy Inducible regulatory system and use thereof
NZ522634A (en) 1997-12-03 2004-02-27 Genentech Inc PRO243 encoding a polypeptide with homology to chordin and antibodies and vectors
US20020165143A1 (en) * 1997-12-03 2002-11-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2327457A1 (en) 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2337100C (en) * 1998-08-07 2011-09-20 Immunex Corporation Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same
WO2000008057A2 (en) * 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU1231400A (en) 1998-10-28 2000-06-05 Human Genome Sciences, Inc. 12 human secreted proteins
AU2474700A (en) 1998-12-01 2000-06-19 Genentech Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
US6787638B1 (en) 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1137664A2 (en) 1998-12-10 2001-10-04 Washington University Protein transduction system and methods of use thereof
AU755574B2 (en) 1999-06-30 2002-12-19 Sigma-Aldrich Co. Synthetic peptide immunogens and antibodies thereto
EP1339871B1 (en) * 2000-08-15 2008-10-15 The Johns Hopkins University School Of Medicine Diagnosis and treatment of tumor-suppressor associated disorders
AU2001296301A1 (en) 2000-09-26 2002-04-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
NL2002787C2 (en) 2009-04-23 2010-10-26 Medspray Xmems Bv Atomising body, atomising device, inhaler, manufacturing method of manufacturing an atomising body and assembly method for assembling an atomising device.

Similar Documents

Publication Publication Date Title
US20240325554A1 (en) Methods for treating cancer
US20230129258A1 (en) Heterotandem bicyclic peptide complexes
JP5651583B2 (ja) 自己免疫疾患の治療および/または予防のための薬剤、ならびに制御性t細胞形成のための薬剤
Yang et al. Differential expression of CD8 epitopes amongst porcine CD8‐positive functional lymphocyte subsets
KR20200019211A (ko) T 세포 수용체
JP2019506843A (ja) 抗原特異的cd8+t細胞の産生におけるインターロイキン−10及びその使用方法
JP2022515330A (ja) 多量体t細胞調節ポリペプチド及びその使用方法
CN1317343A (zh) 哺乳动物细胞激动素合成抑制因子的制药用途
JP2016530889A (ja) Hbv感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびhbv抗原結合性の二重特異性または多重特異性ポリペプチド
Leonard et al. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity
US9518113B2 (en) Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory T cell function
JP2007536933A5 (cg-RX-API-DMAC7.html)
US20260015400A1 (en) Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
Bezverbnaya et al. Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma
CN114349869B (zh) 一种双特异性的nk细胞激动剂及制备方法和应用
AU2001274931B2 (en) Reagents for cell selection and methods of use
CN108409830B (zh) 一种人pd-1蛋白胞外段亲和环肽c8及其应用
CN1675242A (zh) 促红细胞生成素中的t-细胞表位
US20110144038A1 (en) Human cd154-binding synthetic peptide and uses thereof
JP2024510577A (ja) 処置
CN102924579B (zh) 一种具有提高人nk及nkt细胞杀伤肿瘤细胞活性的多肽及其应用
WO2021232050A1 (en) Natural killer cell immunotherapy for the treatment or prevention of sars-cov-2 infection
JP2023525822A (ja) 多量体t細胞調節性ポリペプチド及びその使用方法
WO2022105922A1 (zh) 源自于ssx2抗原的短肽
JP4712194B2 (ja) Cd8+細胞を単離する方法、並びに関連するハイブリドーマ細胞、抗体及びポリペプチド